Clinical trials: Clear Cell RCC
Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc)
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Background: Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments. Better treatments are needed.
- Trial name
- NCT05665361
- Testing
- Sasanlimab, Palbocicilib
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Through the neoadjuvant treatment with a combination of Cadonilimab and Lenvatinib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for…
- Trial name
- NCT06138496
- Testing
- Cadonilimab Combined With Lenvatinib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Metastatic Renal Cell Carcinoma
Functional Imaging in the Assessment of mRCC Response to Sunitinib
The aim of this study is to assess whether functional magnetic resonance imaging (MRI) techniques are able to detect which patients with metastatic renal cell carcinoma will derive benefit from treatment with anti-angiogenic…
- Trial name
- NCT01977586
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- United Kingdom
- Sponsor
- Imperial College Healthcare NHS Trust
Clear Cell Metastatic Renal Cell Carcinoma
Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib
Stereotactic radiotherapy (SRT) is a newer type of focused radiation therapy that precisely and accurately delivers high dose radiation to a tumour, while sparing much of the nearby normal organs.
- Trial name
- NCT02019576
- Testing
- Stereotactic radiotherapy
- Where
- 12 sites in Canada
- Volunteers
- 38 people
- Sponsor
- Sunnybrook Health Sciences Centre
Metastatic Renal Cell Carcinoma, Kidney Neoplasm
Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
The purpose of the open-label INDIGO-study is to examine whether a first line individualized treatment strategy based on DNA and RNA analyses from the patient's tumor is feasible.
- Conditions
- Metastatic Renal Cell Carcinoma, Kidney Neoplasm, Urologic Neoplasms, Urogenital Neoplasms
- Trial name
- INDIGO (NCT04644432)
- Testing
- Medication (A specification is listed under each arm), Patient reported outcomes measurement
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Herlev and Gentofte Hospital
Clear Cell Renal Cell Carcinoma
ABEMA Alone or in COMBO With MK-6482
This research study will assess whether abemaciclib alone or in combination with MK-6482 are safe and effective in slowing down the growth of clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT04627064
- Testing
- Abemaciclib, MK-6482
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
The study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care.
- Conditions
- Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
- Trial name
- EXACT (NCT06863311)
- Testing
- XL092, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Karie Runcie
Solid Tumor, Small Cell Lung Cancer (SCLC)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
- Trial name
- NCT07517198
- Testing
- EXS74539
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
- Conditions
- Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma
- Trial name
- NCT03679767
- Testing
- Retifanlimab
- Where
- 52 sites in United States, Austria and 6 more
- Volunteers
- 121 people
- Sponsor
- Incyte Corporation
Carcinoma, Renal Cell
Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma
The purpose of this study was to evaluate the safety and efficacy of CAP-232 in the treatment of patients with previously treated (refractory) renal cell carcinoma
- Trial name
- NCT00422786
- Testing
- CAP-232
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- Thallion Pharmaceuticals
Kidney Cancer
Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00866320
- Testing
- sorafenib tosylate
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Kidney Cancer
Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00908739
- Testing
- gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Sponsor
- Case Comprehensive Cancer Center
Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
This phase I trial tests the safety and effectiveness of nivolumab and ipilimumab with and without EXL01 for the treatment of renal cell cancer that has spread from where it first started (primary site) to other places in the…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma
- Trial name
- NCT07128680
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Metastatic Clear Cell Renal Cell Carcinoma
Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma
This is an open labeled phase I dose escalation study of hydroxychloroquine (HCQ) and RAD001 in patients with advanced renal cell carcinoma followed by a Phase II trial of RAD001 with HCQ.
- Trial name
- NCT01510119
- Testing
- Hydroxychloroquine, RAD001
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Advanced Clear Cell Renal Cell Carcinoma
A Clinical Study of 6MW3211 in Patients With Renal Cancer
single arm, non-randomized, multicenter, open label, phase 2 clinical trial in patients with advanced clear cell renal cacer
- Trial name
- NCT05440045
- Testing
- 6MW3211
- Volunteers
- 30 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
This pilot phase I trial studies the side effects and best way to give stereotactic body radiation therapy and T-cell infusion in treating patients with metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01943188
- Testing
- stereotactic body radiation therapy, cyclophosphamide, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
Metastatic Clear Cell Renal Cell Carcinoma
Imaging Study in Metastatic Clear Cell RCC.
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).
- Trial name
- NCT07671417
- Testing
- RYZ512
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 10 people
- Sponsor
- RayzeBio, Inc.
Renal Cancer
Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Usually, doctors monitor kidney cancer with CT scans to measure the size of tumors. Sometimes, even when a drug is working, it can take several months before the effects are seen on a regular CT scan.
- Trial name
- NCT01582204
- Testing
- 124IcG250
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center